RecruitingPhase 2NCT07157254
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
Studying Angelman syndrome due to a point mutation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Medical DirectorUltragenyx Pharmaceutical Inc
- Intervention
- No intervention(other)
- Enrollment
- 60 enrolled
- Eligibility
- 1-64 years · All sexes
- Timeline
- 2025 – 2030
Study locations (22)
- Clinical Trial Site, Los Angeles, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Clinical Trial Site, Baltimore, Maryland, United States
- Clinical Trial Site, Kansas City, Missouri, United States
- Rare Disease Research, Hillsborough, North Carolina, United States
- Akron Children's Hospital, Akron, Ohio, United States
- Clinical Trial Site, Philadelphia, Pennsylvania, United States
- UT Health Austin, Austin, Texas, United States
- Carum Research Inc., Dallas, Texas, United States
- Clinical Trial Site, Pilar, Buenos Aires, Argentina
- Clinical Trial Site, Curitiba, Paraná, Brazil
- Clinical Trial Site, Santa Cecília, Porto Alegre, Brazil
- Clinical Trial Site, Marseille, France
- Clinical Trial Site, Paris, France
- Clinical Trial Site, Ramat Gan, Israel
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07157254 on ClinicalTrials.govOther trials for Angelman syndrome due to a point mutation
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07417137A Natural History Study of Angelman SyndromeMassachusetts General Hospital
- RECRUITINGPHASE1, PHASE2NCT07181837A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman SyndromeMavriX Bio, LLC
- RECRUITINGNCT06737718Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman SyndromeAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE3NCT06617429Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Ultragenyx Pharmaceutical Inc
- ENROLLING BY INVITATIONPHASE3NCT06415344Long-term Extension of GTX-102 in Angelman SyndromeUltragenyx Pharmaceutical Inc
- RECRUITINGPHASE1, PHASE2NCT05127226HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromeIonis Pharmaceuticals, Inc.
- RECRUITINGNCT06229769Natural History Study for Patients With Angelman SyndromeCentre Hospitalier Universitaire de Liege
- RECRUITINGNCT05293184The Global Angelman Syndrome RegistryFoundation for Angelman Syndrome Therapeutics, Australia
See all trials for Angelman syndrome due to a point mutation →